We are live on ! Find out more
MG

Meditor Group Portfolio holdings

AUM $48.1M
1-Year Est. Return 38.67%
This Fund
S&P 500
This Quarter Est. Return
-16.19%
1 Year Est. Return
+38.67%
3 Year Est. Return
+41.15%
5 Year Est. Return
+72.2%
10 Year Est. Return
+1,065.64%
AUM
$150M
AUM Growth
-$51.9M
Cap. Flow
-$17.5M
Cap. Flow %
-11.62%
Top 10 Hldgs %
100%
Holding
4
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EXEL icon
1
Exelixis
EXEL
$13.9B
$107M 71.1%
6,816,300
-904,000
-12% -$17.5M
ESPR
2
DELISTED
Esperion Therapeutics
ESPR
$29.9M 19.92%
4,468,835
INDA icon
3
iShares MSCI India ETF
INDA
$6.71B
$6.98M 4.64%
171,200
EPI icon
4
WisdomTree India Earnings Fund ETF
EPI
$2.02B
$6.53M 4.34%
213,800

Similar funds

Meditor Group's Q3 2022 Portfolio in Review

As of Q3 2022, Meditor Group held 4 positions worth $150M, down 26% from $202M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Meditor Group withdrew a net $17.5M in Q3 2022, reducing 1 holding. Its largest reduction was Exelixis, cutting an estimated $17.5M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.

  • Meditor Group's biggest Q3 2022 reduction was Exelixis, cutting an estimated $17.5M.
  • Meditor Group's ten largest holdings make up 100% of its $150M portfolio in Q3 2022.
  • Meditor Group opened 0 new positions and closed 0 in Q3 2022.
  • Meditor Group's portfolio value fell 26% quarter-over-quarter to $150M.

Based on Meditor Group's 13F filing for Q3 2022, filed 7 Nov 2022.